Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255544 | 0.89 | NOX1 (0.51) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1257139 | 0.88 | ADORA1 (0.52) | L3MBTL1ADORA3ADORA1ADORA2AUSP2 | |
| SCHEMBL1255995 | 0.87 | ADORA1 (0.64) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1255424 | 0.87 | SMN1; SMN2 (0.61) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1254654 | 0.83 | L3MBTL1 (0.57) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1255437 | 0.83 | ADORA2A (0.68) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1256234 | 0.83 | ADORA2A (0.68) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1255326 | 0.82 | L3MBTL1 (0.47) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1256703 | 0.81 | ADORA1 (0.63) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL1254039 | 0.81 | ADORA3 (0.67) | L3MBTL1ADORA3ADORA1ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-1700856-B1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8420827-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | L3MBTL1 436/4885ADORA3 394/4885ADORA1 954/4885 |
| US-20110105486-A1 | THIAZOLE DERIVATIVES | CHD8, CYP2C8, THRA | L3MBTL1 702/4885ADORA3 307/4885ADORA1 720/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | L3MBTL1 2618/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | L3MBTL1 2473/4885ADORA3 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.